论文部分内容阅读
[目的]探讨RAS相关区域家族1A(RASSF1A)蛋白在原发性肝细胞癌(HCC)组织芯片中的表达及其临床意义。[方法]98例HCC,89例非癌肝组织及24例癌旁肝组织构建组织微阵列。应用免疫组化技术检测RASSF1A蛋白的表达水平,并分析其与HCC临床病理特征的关系。[结果](1)组织微阵列利用率为97.16%(205/211);(2)RASSF1A蛋白明确定位于肝细胞胞浆内;(3)HCC组织中的RASSF1A蛋白的阳性率为39.58%(38/96),明显低于非癌组织组57.65%(49/85,P=0.015)及癌旁肝组织组66.67%(16/24,P=0.017);(4)HCC中临床TNM分期Ⅰ,Ⅱ期RASSF1A阳性率为57.38%(35/61),明显高于Ⅲ,Ⅳ期8.57%(3/35,P=0.000);(5)HCC中无转移组RASSF1A阳性率为63.64%(28/44),明显高于转移组4.88%(2/41,P=0.000);(6)RASSF1A蛋白表达在﹤50岁组(16/54,29.63%),AFP≥400μg/L组(14/55,25.45%),有门脉癌栓组(3/31,6.98%),包膜浸润组(16/64,25%)及多个结节组(5/31,16.13%)明显低于≥50岁组(22/42,52.38%,P=0.024),AFP﹤400μg/L组(24/41,58.54%,P=0.002),无门脉癌栓组(35/65,53.85%,P=0.000),无包膜浸润组(22/32,68.75%,P=0.000)及单个结节组(33/65,50.77%,P=0.000),与性别、有无肝硬化、HCC分化程度及肿瘤大小无关(P﹥0.05)。[结论]应用组织芯片大规模高效检测临床组织样本是可行的,具有快速、方便、经济、准确的特点。RASSF1A表达缺失在HCC的发生发展中起重要作用;检测RASSF1A蛋白指标有助于HCC诊断和判断患者预后。
[Objective] To investigate the expression of RASSF1A protein in primary hepatocellular carcinoma (HCC) tissue microarray and its clinical significance. [Method] Tissue microarray was constructed in 98 cases of HCC, 89 cases of non-cancerous liver tissue and 24 cases of adjacent liver tissue. The expression of RASSF1A protein was detected by immunohistochemistry and its relationship with the clinicopathological features of HCC was analyzed. [Results] (1) The utilization rate of tissue microarray was 97.16% (205/211). (2) RASSF1A protein was localized in the cytoplasm of hepatocytes. (3) The positive rate of RASSF1A protein in HCC tissues was 39.58% 38/96), which was significantly lower than that of non-cancerous tissue (57.65%, P = 0.015) and adjacent non-cancerous tissue (66.67%, P = 0.017) . The positive rate of RASSF1A in stage Ⅱ was 57.38% (35/61), which was significantly higher than that in stage Ⅲ and Ⅳ (8.57%, 3/35, P = 0.000). (5) The positive rate of RASSF1A in non-metastatic HCC was 63.64% / 44), which was significantly higher than that of the metastasis group (4.88%, 2/41, P = 0.000). (6) The expression of RASSF1A protein was significantly higher in the group of <50 years old (16/54, 29.63% 55, 25.45%), portal vein tumor thrombus group (3 / 31,6.98%), enveloping group (16 / 64,25%) and multiple nodules group (5 / 31,16.13% (P <0.05), AFP <400μg / L group (24/41, 58.54%, P = 0.002), portal vein tumor thrombus group (35/65, 53.85%, P = (P = 0.000), non-enveloped infiltration group (22/32, 68.75%, P = 0.000) and single nodule group (33/65, 50.77%, P = 0.000) Degree and tumor size had no correlation (P> 0.05). [Conclusion] It is feasible to use tissue microarray for large-scale and high-efficiency detection of clinical tissue samples, which is fast, convenient, economical and accurate. The loss of RASSF1A expression plays an important role in the development of HCC. The detection of RASSF1A protein is helpful for HCC diagnosis and prognosis.